# Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693

> **NCT00493818** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 70 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** GSK690693

## Key facts

- **NCT ID:** NCT00493818
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-04
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2017-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00493818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00493818, "Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00493818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*